1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)

1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, commonly known as DOTA, is a macrocyclic chelating agent used extensively in the development of radiopharmaceuticals and contrast agents. It is not a biological target such as a receptor or enzyme, but rather a chemical scaffold that facilitates the delivery of diagnostic or therapeutic metal ions to specific sites in the body (PubChem CID 65036). DOTA forms exceptionally stable complexes with trivalent lanthanides and other radionuclides, ensuring that toxic free metals are not released into systemic circulation (PubMed: 11055291). In clinical practice, DOTA is often conjugated to peptides or antibodies that target specific biomarkers, such as the somatostatin receptor in neuroendocrine tumors or PSMA in prostate cancer (DrugBank DB12855). This theranostic approach allows for both the visualization of disease via PET or MRI and the targeted destruction of malignant cells via beta-emitting isotopes. Its high kinetic stability and versatility make it a gold standard in coordination chemistry for medical applications.

Other names

TetraxetanDOTA1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acidDOTA-chelate

DOTA acts as a polydentate chelating agent that sequesters trivalent metal ions (such as lanthanides or radionuclides) into a highly stable, kinetically inert macrocyclic cage (PubChem CID 65036). In radiopharmaceuticals, it serves as a bifunctional linker that holds the radioactive isotope securely while being conjugated to a targeting vector, such as a peptide, which then binds to specific cellular receptors to deliver localized radiation (PubMed: 24354371, DrugBank DB09130).